会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Nucleic acid analysis techniques
    • 核酸分析技术
    • US06344316B1
    • 2002-02-05
    • US08882649
    • 1997-06-25
    • David J. LockhartMark CheeKevin GundersonLai ChaoqiangLisa WodickaMaureen T. CroninDanny LeeHuu M. TranHajime Matsuzaki
    • David J. LockhartMark CheeKevin GundersonLai ChaoqiangLisa WodickaMaureen T. CroninDanny LeeHuu M. TranHajime Matsuzaki
    • C12Q168
    • C07H19/052C07H19/12C07H21/00C12Q1/6809C12Q1/6837C12Q2600/156C40B40/00G06F19/20G06F19/22C12Q2525/161C12Q2565/501C12Q2561/125
    • The present invention provides a simplified method for identifying differences in nucleic acid abundances (e.g., expression levels) between two or more samples. The methods involve providing an array containing a large number (e.g. greater than 1,000) of arbitrarily selected different oligonucleotide probes where the sequence and location of each different probe is known. Nucleic acid samples (e.g. mRNA) from two or more samples are hybridized to the probe arrays and the pattern of hybridization is detected. Differences in the hybridization patterns between the samples indicates differences in expression of various genes between those samples. This invention also provides a method of end-labeling a nucleic acid. In one embodiment, the method involves providing a nucleic acid, providing a labeled oligonucleotide and then enzymatically ligating the oligonucleotide to the nucleic acid. Thus, for example, where the nucleic acid is an RNA, a labeled oligoribonucleotide can be ligated using an RNA ligase. In another embodiment, the end labeling can be accomplished by providing a nucleic acid, providing labeled nucleoside triphosphates, and attaching the nucleoside triphosphates to the nucleic acid using a terminal transferase.
    • 本发明提供用于鉴定两个或多个样品之间的核酸丰度差异(例如,表达水平)的简化方法。 所述方法包括提供包含大量(例如大于1,000个)任意选择的不同寡核苷酸探针的阵列,其中每个不同探针的序列和位置是已知的。 来自两个或更多个样品的核酸样品(例如mRNA)与探针阵列杂交,并检测杂交模式。 样本之间的杂交模式的差异表明这些样品之间各种基因的表达差异。 本发明还提供了一种终止标记核酸的方法。 在一个实施方案中,该方法包括提供核酸,提供标记的寡核苷酸,然后将寡核苷酸酶连接到核酸上。 因此,例如,当核酸是RNA时,可以使用RNA连接酶连接标记的寡核糖核苷酸。 在另一个实施方案中,末端标记可以通过提供核酸,提供标记的核苷三磷酸和使用末端转移酶将核苷三磷酸与核酸连接来实现。
    • 6. 发明申请
    • MULTIPLE COMPARTMENT DOSING MODEL
    • 多个舱室配料模型
    • US20100106473A1
    • 2010-04-29
    • US12604855
    • 2009-10-23
    • Daniel J. LockhartDavid J. Lockhart
    • Daniel J. LockhartDavid J. Lockhart
    • G06F17/10
    • G06F19/12
    • The method for modeling a dosing regimen for a medicament includes providing a system having at least two biocompartments. The method determines steady state levels in each of the biocompartments. After that, the method provides for modifying values to calculate an amount of at least one protein in one of the biocompartments to which the protein is being transported. Next, the method calculates and integrates a weighted value of the protein to find a weighted area under the curve. Then, the method calculates and integrates a non-drug value of the protein to find a non-drug area under the curve. Finally, the method evaluates one or more dosing regimens by comparing the weighted area under the curve and the non-drug area under the curve of the protein to determine a net effect of the drug over the time period.
    • 用于建模用于药物的给药方案的方法包括提供具有至少两个生物隔离物的系统。 该方法确定每个生物隔离物中的稳态水平。 之后,该方法提供修饰值以计算蛋白质正在运输到的一个生物隔离物中的至少一种蛋白质的量。 接下来,该方法计算并积分蛋白质的加权值以找到曲线下的加权面积。 然后,该方法计算并整合蛋白质的非药物值,找出曲线下的非药物区域。 最后,该方法通过比较曲线下的加权面积和蛋白质曲线下的非药物面积来评估一种或多种给药方案,以确定药物在该时间段内的净效应。